Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

In order to boost immune responses in persons in whom highly active antiretroviral therapy (HAART) was initiated within 120 days of the onset of symptoms of newly acquired human immunodeficiency virus type 1 (HIV-1) infection, we administered vaccines containing a canarypox virus vector, vCP1452, wi...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	J Virol
Autori principali:	Jin, Xia, Ramanathan, Jr., Murugappan, Barsoum, Shady, Deschenes, Geoffrey R., Ba, Lei, Binley, James, Schiller, Daryl, Bauer, Daniel E., Chen, Donald C., Hurley, Arlene, Gebuhrer, Lucette, El Habib, Raphaelle, Caudrelier, Pierre, Klein, Michel, Zhang, Linqi, Ho, David D., Markowitz, Martin
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2002
Soggetti:	Vaccines and Antiviral Agents
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC135946/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11836398/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.76.5.2206-2216.2002
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!